|
Post by kite on Aug 29, 2018 8:03:18 GMT -5
WESTLAKE VILLAGE, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that it will present at upcoming conferences. Rodman & Renshaw 20th Annual Global Investment Conference on Wednesday, September 5, 2018 at 9:35 am (ET) at the St. Regis Hotel in New York City Cantor Fitzgerald Global Healthcare Conference on Tuesday, October 2, 2018 at 1:40 pm (ET) at the Intercontinental New York Barclay Hotel in New York City Presenting from the Company will be its Chief Executive Officer, Michael Castagna. Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Company's website at www.mannkindcorp.com. About MannKind Corporation MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com. Company Contact: Rose Alinaya SVP Investor Relations 818-661-5000 ir@mannkindcorp.com Source: MannKind Corporation
|
|
|
Post by sportsrancho on Aug 29, 2018 8:48:30 GMT -5
|
|
|
Post by ptass on Aug 29, 2018 11:53:41 GMT -5
It seem like every time one of these events is scheduled dilution occurs soon after.
|
|
|
Post by sportsrancho on Aug 29, 2018 12:11:39 GMT -5
It seem like every time one of these events is scheduled dilution occurs soon after. Not the last time. So I’m not going to assume this time, would be nice to get an upgrade from Cantor Fitzgerald!
|
|
|
Post by traderdennis on Aug 29, 2018 12:34:43 GMT -5
It seem like every time one of these events is scheduled dilution occurs soon after. Not the last time. So I’m not going to assume this time, would be nice to get an upgrade from Cantor Fitzgerald! The last conference the sock price was 2.00. Now price is 1.10.
|
|
|
Post by sportsrancho on Aug 29, 2018 12:36:43 GMT -5
Not the last time. So I’m not going to assume this time, would be nice to get an upgrade from Cantor Fitzgerald! The last conference the sock price was 2.00. Now price is 1.10. And what does one have to do with the other? Neither has to do with the ATM.
|
|
|
Post by mytakeonit on Aug 29, 2018 13:39:43 GMT -5
If you buy a 3 pack of socks ... it'll be cheaper.
|
|
|
Post by mike0475 on Aug 29, 2018 13:55:07 GMT -5
At least they’re attending.
|
|
|
Post by jonny80s on Aug 29, 2018 15:00:51 GMT -5
I understand the need to present at these conferences and I understand the need to promote the companies attendance/presentation (the glimmer of hope). Honestly though, if legitimate funding has never occurred with the previous 5+ years of presenting at these conferences, what would make anyone believe that this year is the year?
Are they are going in with legitimate numbers concerning Afrezza's promotional response or pipeline opportunities....? Pipeline opportunities are a no go if funding for Afrezza marketing is not obtained. That leaves one route: money for a no holds barred marketing campaign.
|
|
|
Post by nylefty on Aug 29, 2018 16:13:22 GMT -5
I understand the need to present at these conferences and I understand the need to promote the companies attendance/presentation (the glimmer of hope). Honestly though, if legitimate funding has never occurred with the previous 5+ years of presenting at these conferences, what would make anyone believe that this year is the year? Remember that wise old saying: If at first you don't succeed, give up.
|
|
|
Post by awesomo on Aug 29, 2018 18:01:41 GMT -5
I understand the need to present at these conferences and I understand the need to promote the companies attendance/presentation (the glimmer of hope). Honestly though, if legitimate funding has never occurred with the previous 5+ years of presenting at these conferences, what would make anyone believe that this year is the year? Remember that wise old saying: If at first you don't succeed, give up. “The definition of insanity is doing the same thing over and over again, but expecting different results”. - Albert Einstein
|
|
|
Post by barnstormer on Aug 29, 2018 18:22:59 GMT -5
They have presented at both of these annual events before. They need to provide an agenda that updates on progress in Brazil with Biomm, progress with Cipla in India and what Tanner is doing to provide distribution of Afrezza and the pediatric study. An estimate of when shipments to these counties is essentail. Mike also needs to have a compelling story for TrepT. Anything else will have the analysts and investors heading for a potty break before Mike gets to the podium. They have heard the Afrezza story before and should have heard about STAT by now. It's time to shine or quit exposing the fact that progress has been hellaciously slow. If there is ever a time to provide "clarity" it is before the presentations. C'mon Mike you can do this!
|
|
sky
Lab Rat
Posts: 46
Sentiment: Long
|
Post by sky on Aug 29, 2018 19:02:29 GMT -5
Couldn't have said it any better.....😡
|
|
|
Post by nylefty on Aug 29, 2018 19:41:04 GMT -5
Remember that wise old saying: If at first you don't succeed, give up. “The definition of insanity is doing the same thing over and over again, but expecting different results”. - Albert Einstein Einstein never said that: www.history.com/news/here-are-6-things-albert-einstein-never-said “The Ultimate Quotable Einstein,” an authoritative complication of his most memorable utterances, identified the quote as a misattribution, and mentioned its use in the 1983 novel “Sudden Death” by Rita Mae Brown. On his website, Quote Investigator, O’Toole traced, the link between insanity and repetition back to at least the 19th century, but noted its use in a Narcotics Anonymous pamphlet as well as novels (including Brown’s), TV shows and various other sources.
And if MannKind didn't take part in these events there would be howls of protest on this board.
|
|
|
Post by mnholdem on Aug 29, 2018 20:03:43 GMT -5
They have presented at both of these annual events before. They need to provide an agenda that updates on progress in Brazil with Biomm, progress with Cipla in India and what Tanner is doing to provide distribution of Afrezza and the pediatric study. An estimate of when shipments to these counties is essentail. Mike also needs to have a compelling story for TrepT. Anything else will have the analysts and investors heading for a potty break before Mike gets to the podium. They have heard the Afrezza story before and should have heard about STAT by now. It's time to shine or quit exposing the fact that progress has been hellaciously slow. If there is ever a time to provide "clarity" it is before the presentations. C'mon Mike you can do this! An accurate assessment of the market share of Technosphere API in the pipeline would be good, but the CEO needs to present specific and compelling reasons why MannKind believes that Afrezza will become the Standard of Care among Type 1 mealtime insulins and for treatment of early-stage Type 2 diabetes. One of the CEO's objectives is to convince several analysts to publish Buy recommendations for MNKD stock with significantly higher 1-Yr price targets. Repeating data, charts and graphs will not be sufficient. CEO Castagna needs to succinctly communicate his vision for MannKind Corporation.
|
|